Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
Unveiling mechanisms of resistance to immunotherapy: Tumor intrinsic JAK2 downmodulation leads to IFN-gamma deficient response and acquired resistance to T cell redirection therapies
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
Konstantinos Liapis & Ioannis Kotsianidis, on behalf of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes.